XTL Biopharmaceuticals Sponsored ADR (XTLB) AI Stock Analysis

• Market Cap: $11.51M
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: N/A
• EPS Growth: 65.38%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 8,813,852
• 10 Day Avg. Volume: 300,985
• 30 Day Avg. Volume: 1,636,999
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.51
• Price to Sales (P/S): 30.29
• P/FCF Ratio: -8.17
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.

XTL Biopharmaceuticals Sponsored ADR Business Overview & Revenue Model

Company Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

How the Company Makes Money

XTL Biopharmaceuticals generates revenue primarily through the development and commercialization of proprietary drug candidates targeting autoimmune diseases and cancer. The company may earn money from licensing agreements, milestone payments, and royalties related to its drug development programs. Key revenue streams include partnerships with other pharmaceutical companies for the co-development or out-licensing of its drug candidates, as well as potential sales of approved products. Additionally, the company may receive research grants and funding from governmental or non-governmental organizations to support its R&D activities.

XTL Biopharmaceuticals Sponsored ADR Financial Statement Overview

Summary

XTL Biopharmaceuticals Ltd. faces ongoing financial headwinds, with significant net losses and negative EBIT margins. Despite a slight improvement in stockholders' equity, the company struggles with high liabilities and negative cash flows, reflecting operational inefficiencies typical in the biotech sector.

Income Statement

The income statement reflects significant challenges with persistent net losses and negative EBIT margins due to the absence of revenue. The company's profitability trajectory is concerning, with inconsistent net income figures over the years. The lack of revenue growth further exacerbates the financial instability, indicating potential operational inefficiencies in the biotechnology sector.

Balance Sheet

The balance sheet shows a slight improvement in stockholders' equity, moving from negative to positive in the most recent year. However, the overall financial stability remains weak due to high liabilities relative to assets. The company benefits from a low debt profile, but the equity ratio indicates a fragile financial structure that may pose risks in sustaining operations.

Cash Flow

The cash flow statement reveals consistent negative free cash flow and operating cash flow, highlighting liquidity challenges. The cash flow to net income ratios indicate inefficiencies in converting net losses to positive cash flow. Although there is some improvement in cash flow from investing activities, the overall cash flow management remains a concern.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	451.00K	0.00	0.00	0.00	0.00
Gross Profit	3.00K	0.00	-1.00K	0.00	-1.00K
EBITDA	-930.00K	-764.00K	-879.00K	-1.03M	-947.00K
Net Income	-1.03M	-1.78K	-1.35M	435.00K	-782.00K
Balance Sheet
Total Assets	8.55M	2.43M	4.19M	6.62M	6.50M
Cash, Cash Equivalents and Short-Term Investments	1.14M	2.01M	3.72M	6.13M	6.04M
Total Debt	138.00K	0.00	0.00	0.00	0.00
Total Liabilities	3.12M	206.00K	187.00K	1.28M	254.00K
Stockholders Equity	5.43M	2.22M	4.00M	5.33M	3.61M
Cash Flow
Free Cash Flow	-1.67M	-707.00K	-901.00K	-1.05M	-851.00K
Operating Cash Flow	-1.62M	-707.00K	-901.00K	-1.05M	-850.00K
Investing Cash Flow	-844.00K	41.00K	36.00K	8.00K	32.00K
Financing Cash Flow	1.45M	0.00	0.00	385.00K	0.00

XTL Biopharmaceuticals Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTLB, the sentiment is Negative. The current price of 1.28 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.28, and below the 200-day MA of 1.36, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.93 is Neutral, neither overbought nor oversold. The STOCH value of 4.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XTLB.

XTL Biopharmaceuticals Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LPCN	52 Neutral	$15.23M	-3.31	-23.51%	―	-45.78%	47.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COCP	40 Underperform	$13.43M	-0.86	-110.56%	―	―	29.97%
XTLB	39 Underperform	$11.51M	―	―	―	―	65.38%
CARM	37 Underperform	$1.47M	-0.03	―	―	-48.01%	33.60%
EDSA	35 Underperform	$19.21M	-2.02	-69.64%	―	―	22.63%
ALLR	28 Underperform	$21.93M	―	-150.58%	―	―	99.59%